Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Immunotherapy" wg kryterium: Temat


Tytuł:
Alergenowo-swoista immunoterapia u dzieci
Allergen-specific immunotherapy in children
Autorzy:
Maślany, Anna
Jung, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1031900.pdf
Data publikacji:
2011
Wydawca:
Medical Communications
Tematy:
SCIT
SLIT
allergy
immunotherapy
pathogenesis
subcutaneous immunotherapy
sublingual immunotherapy
alergia
immunoterapia
scit
slit
patogeneza
Opis:
Allergen-specific immunotherapy (ASI) allows for a treatment and influences on the course of, the allergic, IgE-dependent diseases. ASI induces allergen tolerance resulting in a reduction or disappearance of clinical symptoms of allergy. One hundred years ago, in 1910 exactly, Noon published his landmark study. Since then, the knowledge of its mechanisms, indications for ASI and routes of administration of allergen is systematically being broaden. Currently used forms of allergens allow to minimize serious side effects related to the ASI, which were observed in the initial trials of therapy. This paper presents current views on the pathomechanisms of immunotherapy, rules for an application of immunotherapy and possibility of using ASI in atopic diseases. The main reason for this form of a treatment is inability to eliminate the allergen from patient’s environment with a high probability of severe clinical symptoms after contact with the allergen. The best results are achieved in case of hypersensitivity to hymenoptera venom and treatment of allergic rhinitis, allergic conjunctivitis and asthma associated with allergy to grass pollen, trees, weeds and dust mites. Treatment of monoallergy gives better results compared to the sensitisation to multiple allergens. For some of the cases, due inability of pharmacotherapy or its ineffectiveness, one could consider usage of ASI for patients with allergy tied with other allergens. Currently this method is not approved for the treatment of food allergy. This paper quotes meta-analysis, carried out in recent years, evaluating the efficiency of the most popular current methods of immunotherapy – subcutaneous (SCIT) and sublingual (SLIT) – in the treatment of asthma and allergic rhinitis. The publications cited below clearly show that these methods are effective in reducing and eliminating allergy symptoms. This paper presents the latest promising route of administration allergen – percutaneous immunotherapy, particularly beneficial for younger patients. In the era of great advances in medicine, we can expect further improvements of ASI, elimination of serious side effects and widening group of patients eligible for this form of therapy.
Alergenowo-swoista immunoterapia (ASI) umożliwia leczenie i wpływ na przebieg alergicznych schorzeń IgE-zależnych. W wyniku jej działania następuje indukcja tolerancji alergenu, a w rezultacie – zmniejszenie lub ustąpienie objawów klinicznych alergii. Od daty wydania (1910 r.) publikacji Noona, uważanej za przełomową w rozwoju immunoterapii, mija 101 lat. W tym czasie systematycznie poszerzano wiedzę na temat mechanizmów jej działania, wskazań do stosowania ASI oraz formy podawania alergenu. Obecnie stosowane rodzaje ASI pozwalają na zminimalizowanie poważnych objawów niepożądanych, które obserwowano w początkowych próbach terapii. W pracy przedstawiono współczesne poglądy na temat patomechanizmów immunoterapii, zasad jej podawania oraz możliwości stosowania ASI w przypadku schorzeń atopowych. Podstawowym wskazaniem do tej metody leczenia jest brak możliwości wyeliminowania alergenu ze środowiska pacjenta przy dużym prawdopodobieństwie wystąpienia ciężkich objawów klinicznych uczulenia po kontakcie z alergenem. Najlepsze rezultaty osiąga się w przypadku nadwrażliwości na jady owadów błonkoskrzydłych oraz leczenia alergicznego nieżytu nosa, alergicznego zapalenia spojówek, a także astmy związanej z alergią na pyłki traw, drzew, chwastów i roztoczy kurzu domowego. Leczenie monoalergii daje lepszą skuteczność w porównaniu z uczuleniem na wiele alergenów. W wybranych przypadkach przy braku możliwości stosowania farmakoterapii lub jej nieskuteczności można rozważyć użycie ASI u pacjentów z alergią związaną z innymi alergenami. Aktualnie nie jest to metoda zaakceptowana w leczeniu alergii pokarmowej. W pracy przytoczono metaanalizy przeprowadzone w ostatnich latach, oceniające skuteczność dwóch najpopularniejszych obecnie metod immunoterapii – SCIT (śródskórnej) oraz SLIT (podjęzykowej) – w leczeniu astmy oraz alergicznego nieżytu nosa. Z cytowanych poniżej publikacji wynika, że są to metody skuteczne, zmniejszające lub eliminujące objawy choroby u alergików. Przedstawiono również najnowsze, bardzo obiecujące drogi podania alergenu, w tym przezskórną immunoterapię, szczególnie korzystną u najmłodszych pacjentów. W dobie ogromnego postępu medycyny należy oczekiwać dalszego udoskonalania ASI, eliminacji poważnych objawów ubocznych oraz rozszerzenia grupy pacjentów objętych tą formą terapii.
Źródło:
Pediatria i Medycyna Rodzinna; 2011, 7, 3; 212-217
1734-1531
2451-0742
Pojawia się w:
Pediatria i Medycyna Rodzinna
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Neoantigen therapeutic cancer vaccines: a promising approach to personalized immunotherapy
Autorzy:
Poboży, Kamil
Domańska, Julia
Domański, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/44424306.pdf
Data publikacji:
2023-09-18
Wydawca:
Medical Education
Tematy:
cancer vaccine
personalized immunotherapy
neoantigen
immunotherapy
tumour microenvironment
immune escape
Opis:
The tumour microenvironment diversity among patients poses a challenge for conventional therapies, leading to limited efficacy. Furthermore, conventional methods are inherently associated with a negative impact on healthy tissues. Personalized immunotherapy, focused on individual tumor characteristics, has emerged as a potential solution. Neoantigens, unique antigens arising from tumour-specific mutations, play a crucial role in personalized therapy. Identifying and utilizing neoantigens through therapeutic vaccines can induce an immune response specifically against tumour cells, offering a more targeted and less toxic for healthy tissues approach to cancer treatment. The vaccines can potentially lead to tumour regression and improved outcomes. The effectiveness of this therapy is still limited due to phenomena such as immune escape. However, ongoing scientific research, technological advancements, and emerging combination therapies offer hope for the success of neoantigen-based therapeutic cancer vaccines, ushering in a new era in personalized oncology.
Źródło:
OncoReview; 2023, 13, 4; 93-98
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Advanced skin melanoma – systemic treatment
Autorzy:
Kruczała, Maksymilian
Ziobro, Marek
Grela-Wojewoda, Aleksandra
Cedrych, Ida
Powiązania:
https://bibliotekanauki.pl/articles/1065316.pdf
Data publikacji:
2015
Wydawca:
Medical Education
Tematy:
immunotherapy
melanoma
systemic therapy
Opis:
In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in systemic treatment. Recently, a significant progress in melanoma therapy has been observed. Introducing targeted therapy or immunotherapy significantly improved treatment outcomes. This review paper presents current knowledge on systemic treatment of advanced melanoma, including treatment availability in Poland.
Źródło:
OncoReview; 2015, 5, 3; A133-138
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Immunoterapia podjęzykowa
Sublingual immunotherapy
Autorzy:
Grad, Anna
Bartoszewicz, Ludmiła
Kalicki, Bolesław
Koszycka, Anna
Jung, Anna
Żuber, Janusz
Powiązania:
https://bibliotekanauki.pl/articles/1031259.pdf
Data publikacji:
2009
Wydawca:
Medical Communications
Tematy:
adverse reactions
allergenic vaccinations
local immunotherapy
specific immunotherapy
sublingual immunotherapy
immunoterapia swoista
immunoterapia miejscowa
immunoterapia podjęzykowa
szczepionki alergenowe
objawy niepożądane
Opis:
The specific immunotherapy next to the elimination of allergen from patient’s environment is the only causal way of treatment of allergic diseases. It refers to give the patients increasing doses of allergenic vaccination by injectional way or more rarely used non-injectional. Local immunotherapy includes: sublingual immunotherapy – “spit” type and “swallow” type, oral, intranasal, intrabronchial and intraconjunctival immunotherapy. First attempts of using immunotherapy have dated back to the year 1900. Over next hundred years there have been periods of variable interests of this form of treatment. In the nineties of twentieth century an interest of non-injectional form of specific immunotherapy has increased distinctly. Last years research confirms that sublingual immunotherapy can be an alternative to injectional immunotherapy. A necessary condition is using high doses of allergen. SLIT is safe way of treatment and acceptable to patients. Most of observed side effects are connected with immediate exposing mucous membrane to action of allergenic vaccination. Local side effects are usually short-time, they recede spontaneous and doesn’t need to be treated. Vaccinations, which are used in specific immunotherapy, should be standardized by biological tests. Due to it, next series of vaccinations are comparable to the biological model in respect of contents of allergen and power of activity. It is recommended to use maximum four allergens in one vaccination and not to connect seasonal allergens with yearlong ones. Specific immunotherapy can be used seasonal and yearlong, a scheme of yearlong immunotherapy enables giving higher doses of allergenic vaccination and allows to achieve better clinical efficiency. Optimal period of specific immunotherapy isn’t defined ultimately. It is recommended to use immunotherapy not shorter than three to five years.
Immunoterapia swoista (SIT) stanowi jedyne, obok eliminacji alergenu z otoczenia chorego, leczenie przyczynowe chorób alergicznych. Polega na podawaniu choremu wzrastających dawek szczepionki alergenowej drogą iniekcyjną (SCIT) lub rzadziej stosowaną drogą nieiniekcyjną. Do immunoterapii miejscowej zaliczamy: immunoterapię podjęzykową typu spit i typu swallow, immunoterapię doustną, donosową, dooskrzelową i dospojówkową. Pierwsze próby stosowania immunoterapii doustnej sięgają roku 1900. Przez kolejne ponad sto lat ta forma leczenia cieszyła się zmiennym zainteresowaniem. W latach 90. XX wieku wyraźnie wzrosło zainteresowanie nieiniekcyjnymi metodami immunoterapii swoistej. Badania ostatnich lat potwierdzają, że immunoterapia podjęzykowa może być alternatywą dla immunoterapii iniekcyjnej. Warunkiem koniecznym jest stosowanie wysokich dawek alergenu. SLIT jest bezpiecznym i akceptowanym przez chorego sposobem leczenia. Większość obserwowanych objawów ubocznych wiąże się z bezpośrednim narażeniem błony śluzowej na działanie szczepionki alergenowej. Objawy miejscowe są zwykle krótkotrwałe, ustępują samoistnie i nie wymagają leczenia. Szczepionki używane do immunoterapii swoistej powinny być standaryzowane za pomocą testów biologicznych. Dzięki temu kolejne serie szczepionek są porównywalne z wzorcem biologicznym pod względem zawartości alergenu i siły działania. Zaleca się stosowanie w szczepionce maksymalnie 4 alergenów oraz niełączenie w niej alergenów sezonowych i całorocznych. Immunoterapię swoistą można prowadzić sezonowo i całorocznie, schemat całoroczny umożliwia podanie wyższych dawek szczepionki alergenowej, a w związku z tym osiągnięcie lepszej skuteczności klinicznej. Optymalny okres prowadzenia immunoterapii swoistej nie został ostatecznie określony, zaleca się prowadzenie SIT nie krócej niż 3 do 5 lat.
Źródło:
Pediatria i Medycyna Rodzinna; 2009, 5, 3; 216-218
1734-1531
2451-0742
Pojawia się w:
Pediatria i Medycyna Rodzinna
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Advances in active and passive immunotherapy for Alzheimer’s disease– a short review
Postępy w aktywnej i pasywnej immunoterapii w chorobie Alzheimera – krótki przegląd piśmiennictwa
Autorzy:
Tabarkiewicz, Jacek
Powiązania:
https://bibliotekanauki.pl/articles/437734.pdf
Data publikacji:
2016
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
choroba Alzheimera
immunoterapia aktywna
immunoterapia pasywna
Alzheimer’s disease
active immunotherapy
passive immunotherapy
Opis:
STRESZCZENIE Choroby neurodegeneracyjne m.in. choroba Alzheimera (AD) dotykają rocznie miliony nowych pacjentów na całym świecie. Fakt ten spowodował intensywny rozwój terapii modyfikujących przebieg choroby i mogących mieć zastosowanie w AD. Dane przedkliniczne wykazały zaangażowanie układu immunologicznego w patogenezie choroby Alzheimera. Komórki mikrogleju, komórki prezentujące antygen np. komórki dendrytyczne oraz produkty aktywacji dopełniacza odgrywają aktywną rolę w neurodegeneracji. Z drugiej strony niektóre elementy układu odpornościowego mogą być wykorzystane do eliminacji złogów amyloidowych i innych nieprawidłowości związanych z AD. W związku z tym, metody pasywnej i aktywnej immunoterapii są jednym z najszybciej rozwijających się sposobów terapii choroby Alzheimera. Podawanie przeciwciał lub indukcja odpowiedzi immunologicznej przeciwko β-amyloidowi, α-synukleinie lub białku tau są intensywnie badane. Jest to związane z odkryciem, że białka te mogą być celem dla przeciwciał w przypadku ich ekspresji na błonie komórkowej lub w przestrzeni pozakomórkowej. Także stosowanie innych metod immunoterapii pasywnej (podawanie dożylnych immunoglobulin) i aktywnej (szczepionki na bazie DNA) jest związane z pozytywnymi efektami klinicznymi. Kolejne próby kliniczne prowadzą do rozwóju efektywnych i bezpiecznych metod immunoterapii choroby Alzheimera i innych chorób neurodegeneracyjnych.
Disease-modifying alternatives are intensively developed for the treatment of neurodegenerative disorders, a group of diseases that afflict millions of patients annually. The pre-clinical data shown involvement of immune system in the pathogenesis of Alzheimer’s disease (AD). Microglia cells, antigen presenting cells like dendritic cells and products of complement activation take an active part in neurodegeneration. On the other hand, some components of immune system could be used for elimination of amyloid plaques and another structural abnormalities associated with AD. Because of that, passive and active immunotherapies are one of the most developed approaches in therapy of AD. Vaccination against amyloid-ß, α-synuclein, or tau has been extensively explored, especially as the discovery that these proteins may propagate cell-to-cell and be accessible to antibodies when embedded into the plasma membrane or in the extracellular space. Also other methods of passive (intravenous immunoglobulins) and active (DNA based vaccines) are associated with positive clinical outcome. The clinical development of efficient and safe immunotherapies for Alzheimer ’s disease and other neurodegenerative disorders is a field in constant evolution.
Źródło:
Medical Review; 2016, 1; 93-96
2450-6761
Pojawia się w:
Medical Review
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Evaluation of immature monocyte-derived dendritic cells generated from patients with colorectal cancer
Autorzy:
Maciejewski, Ryszard
Radej, Sebastian
Furmaga, Jacek
Chrościcki, Andrzej
Rudzki, Sławomir
Roliński, Jacek
Wallner, Grzegorz
Powiązania:
https://bibliotekanauki.pl/articles/1396521.pdf
Data publikacji:
2013-12-01
Wydawca:
Index Copernicus International
Tematy:
dendritic cells
colon cancer
immunotherapy
Opis:
Dendritic cells are heterogeneous population of the leukocytes and most potent APC in activation of naive T lymphocytes. Therefore the DCs generated in vitro are under research for their application in anti-tumor immunotherapy. The aim of the study was generation of the immature dendritic cells from peripheral blood monocytes collected from colorectal cancer patients and comparison of their ability to endocytosis, cytokine production and immunophenotype to DCs generated from healthy donors. Material and methods. 16 adenocarcinoma stage II patients were included in the study. Dendritic cells were generated in the presence of rhGM-CSF and IL-4. PBMC were isolated from the blood of patients and 16 healthy donors - control group. Immunophenotype, ability of endocytosis of Dextran- FITC as well as intracellular IL-12 expression of the generated dendritic cells was measured using flow cytometry. The cytokines (IL-6, IL-10, IL-12p70, IFN-γ) concentration in the supernatants of DCs culture was measured by ELISA. Results. The percentage of the immature dendritic cells and expression of CD206 and CD209 antigens was significantly higher in patients group (p <0.05 and p <0.001 respectively). Significantly (p <0.001) higher expression of the antigens which initiate the Th2 immune response (CD80-/CD86 + and B7-H2 + / CD209 +) was in the patients group. There were no differences in endocytosis ability and the cytokines (IL-6, IL-10, IL-12p70, IFN-γ) concentration between investigated groups. Conclusions. High immature markers expression on the generated dendritic cells together with identical endocytosis ability in patients group is advantageous in antitumor autologous cells immunotherapy planning. However there is one troubling fact - high expression of markers, which may induce tolerance to particular antigen. It seems to be more reasonable to use the autologous DCs in the antitumor immunotherapy, especially due to the incompatibility in allogenic cells in the context of HLA complex.
Źródło:
Polish Journal of Surgery; 2013, 85, 12; 714-720
0032-373X
2299-2847
Pojawia się w:
Polish Journal of Surgery
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Management challenges and therapeutic strategies for metastatic melanoma – a case report
Autorzy:
Aglio, Andrea M.
Cracchiolo, Salvatore
Impellizzeri, Giuseppe
Górecki, Michał
Powiązania:
https://bibliotekanauki.pl/articles/29519536.pdf
Data publikacji:
2023-09-30
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
metastatic melanoma
peritoneal metastases
immunotherapy
Opis:
Introduction and aim. This case report focuses on a 26-year-old female with metastatic melanoma. It highlights the diagnostic process, initial immunotherapy, disease progression, and successful response to second-line therapy. Emphasizing the importance of early detection, personalized treatment, and adaptive strategies, it provides valuable insights into managing this aggressive form of skin cancer. Description of the case. A 26-year-old Caucasian female presented with a suspicious pigmented lesion on her thigh in 2013. The lesion was confirmed as superficial skin melanoma. No lymph node biopsy was performed. In 2021, she had abdominal pain and imaging revealed melanoma metastasis in the peritoneum, lungs and brain. Genetic testing showed BRAF V600E mutation and PD-L1 expression in tumor cells. She received immunotherapy and radiation for a central nervous system metastases but developed a brain hematoma. Follow-up imaging showed disease progression. She started second-line therapy with iBRAF/iMEK, and her condition rapidly improved with regression of metastatic lesions. Follow-up imaging confirmed significant positive changes and almost complete regression of neoplastic lesions. She continues to receive the targeted therapy and shows a positive response. Conclusion. Early diagnosis improves outcomes in metastatic melanoma. Peritoneal metastases should be considered in patients with abdominal symptoms. The combination of gamma knife radiosurgery with immunotherapy or targeted therapy shows promise for managing brain metastases, but careful patient selection and monitoring are vital due to potential risks. Treatment responses in advanced melanoma vary, with this case highlighting a favorable response to BRAF/MEK inhibitor therapy in a patient with a BRAF gene mutation. Further research and clinical trials are needed to refine treatment approaches and improve outcomes in metastatic melanoma.
Źródło:
European Journal of Clinical and Experimental Medicine; 2023, 3; 663-668
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Diminished expression of ICOS, GITR and CTLA-4 at the mRNA level in T regulatory cells of children with newly diagnosed type 1 diabetes
Autorzy:
Łuczyński, Włodzimierz
Wawrusiewicz-Kurylonek, Natalia
Stasiak-Barmuta, Anna
Urban, Remigiusz
Iłendo, Elżbieta
Urban, Mirosława
Hryszko, Marek
Krętowski, Adam
Górska, Maria
Powiązania:
https://bibliotekanauki.pl/articles/1040597.pdf
Data publikacji:
2009
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
immunotherapy
T-lymphocytes
autoimmunity
FoxP3
Opis:
Diabetes mellitus is one of the most common chronic diseases in children. T regulatory cells (Tregs) modulate response to autoantigens and probably play a role in pathogenesis of type 1 diabetes (T1DM). The aim of the present study was the assessment of T regulatory cells including their percentages and expression of critical genes in these cells in children with newly diagnosed type 1 diabetes. The examined group consisted of 50 children with T1DM. A flow cytometric analysis of T-cell subpopulations was performed using the following markers: anti-CD4, anti-CD25 and anti-CD127 (=IL-7R). Additionally, T regulatory cells were isolated for assessment of mRNA levels for chosen genes with the real-time RT-PCR technique. The percentages of CD4+CD25highCD127dim/- were very low and did not differ between T1DM and control children. We did not observe any statistically significant differences between healthy and diabetic children in mRNA expression for FoxP3, IL-7R (CD127), IL-8RA, IL-10RA, IL-12A, IL-2RA (CD25), IL-21, STAT1, STAT3, SOCS2, SOCS3, TGF-β1-R1, TGF-β-R2 and TBX-21 genes. Interestingly the mRNA level for CTLA-4, ICOS1, IL-23, IL-27, SMAD3 and GITR were lower in Treg cells of children with diabetes compared to the control patients. No disturbances in the percentages of T regulatory cells in patients with diabetes but diminished expression of some elements important in Treg function could be the result of an immunologic imbalance accompanying the onset of the diabetes. The results of our study should be used in future research in the field of immunotherapy in pediatric diabetes.
Źródło:
Acta Biochimica Polonica; 2009, 56, 2; 361-370
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Immunotherapy in alveolar hydatidosis: an alternative to surgery
Autorzy:
Magambo, J.
Tanner, C.E.
Burt, M.D.B.
Powiązania:
https://bibliotekanauki.pl/articles/837091.pdf
Data publikacji:
1998
Wydawca:
Polskie Towarzystwo Parazytologiczne
Tematy:
chemotherapy
hydatidosis
Echinococcus multilocularis
cestode
immunotherapy
Źródło:
Annals of Parasitology; 1998, 44, 3
0043-5163
Pojawia się w:
Annals of Parasitology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Peanut allergy immunotherapy: review of current treatment options
Immunoterapia alergii na orzechy ziemne: przegląd aktualnych metod terapeutycznych
Autorzy:
Jasiura, Adam
Dera, Izabela
Gorzel, Mateusz
Szlachcic, Karolina
Zmonarska, Joanna
Gomułka, Krzysztof
Powiązania:
https://bibliotekanauki.pl/articles/11236593.pdf
Data publikacji:
2022
Wydawca:
Uczelnia Łazarskiego. Oficyna Wydawnicza
Tematy:
food hypersensitivity
immunotherapy
peanut hypersensitivity
sublingual immunotherapy
alergia pokarmowa
immunoterapia
immunoterapia podjęzykowa
alergia na orzechy ziemne
Opis:
Peanut allergy is the most common food allergy in developed countries of Europe and America, affecting nearly 2% of children. Ingestion of peanut proteins even in the minimal amount may result in a dangerous to life or health anaphylactic reaction, thereby being one of the most common causes of anaphylaxis with fatal effect. Possible therapeutic methods for peanut allergy are sought to achieve patients’ desensitization and antigen tolerance. Among currently considered therapies there are oral immunotherapy (OIT), sublingual immunotherapy (SLIT) and epicutaneous immunotherapy (EPIT), however all of them are still in clinical trials. The most effective immunotherapy is OIT, resulting in higher tolerated antygen doses in comparison to sublingual and epicutaneous therapy, though oral immunotherapy has a higher risk of adverse reactions, mostly gastrointestinal and oropharyngeal. It may be advantageous to fuse several immunotherapy methods into sequential schemes. Future studies are required to furtherly evaluate effectiveness and compare mentioned immunotherapy methods of peanut allergy.
Alergia na orzechy ziemne jest najczęściej występującą alergią pokarmową w krajach rozwiniętych Europy i Ameryki, dotykając 2% dzieci. Przyjęcie nawet znikomej ilości białek orzechów ziemnych może skutkować groźną dla zdrowia i życia reakcją alergiczną, przez co alergia na orzechy ziemne jest jedną z najczęstszych przyczyn anafilaksji ze skutkiem śmiertelnym. Poszukuje się możliwych metod terapeutycznych, umożliwiających osiągnięcie desensetyzacji i tolerancji antygenowej na białka orzechów ziemnych. Spośród obecnie rozważanych terapii wymienia się immunoterapię doustną, podjęzykową oraz naskórną, z których wszystkie są nadal na etapie badań klinicznych. Najskuteczniejszą metodą jest immunoterapia doustna, pozwalająca na osiągnięcie wyższych tolerowanych dawek antygenów, w porównaniu do immunoterapii podjęzykowej i naskórnej. Immunoterapia doustna jest jednak obarczona najwyższym ryzykiem występowania niepożądanych reakcji, głównie w obrębie układu pokarmowego i nosogardzieli. Korzystne może okazać się połączenie kilku metod immunoterapii w następujących po sobie schematach. Konieczne są jednak kolejne badania oceniające skuteczność i porównujące ze sobą możliwe metody immunoterapii u pacjentów z alergią na orzechy ziemne.
Źródło:
Review of Medical Practice; 2022, XXVIII, 1-2; 77-84
2956-4441
2956-445X
Pojawia się w:
Review of Medical Practice
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin - prelimary results
Autorzy:
Wasik-Szczepanek, E.
Szymczyk, A.
Kowal, M.
Nogalski, A.
Hus, M.
Powiązania:
https://bibliotekanauki.pl/articles/2081565.pdf
Data publikacji:
2018
Wydawca:
Instytut Medycyny Wsi
Tematy:
chronic lymphocytic leukemia
ofatumumab
monoclonal antibodies
immunotherapy
Opis:
Introduction. Despite significant recent advances in the treatment of chronic lymphocytic leukaemia (CLL), most cases of the disease are still incurable. Treatment with monoclonal antibodies, such as ofatumumab, is one of the new therapeutic options. Objective. Retrospective analysis of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia (CLL) treated in the Haematooncology and Bone Marrow Transplantation Department of the Medical University of Lublin, Poland, during 2011–2013. Materials and method. The analysis included 5 patients (3 women and 2 men), aged 47–65, with Rai stage II-IV CLL, after a few lines of treatment. Three patients received ofatumumab in monotherapy and 2 patients received ofatumumab in combination with cyclophosphamide (50 mg/day) and dexamethasone (40 mg/day). All patients included in the study were diagnosed with an active form of leukaemia with symptoms such as lymphocytosis or massive lymphadenopathy. Results. All patients responded to the treatment. Within the first 8 weeks of the treatment, levels of white blood cells returned to normal in patients with baseline lymphocytosis (3 patients). An increase in platelet levels was reported in 3 patients. Haemoglobin levels were higher or comparable to the baseline values in all studied patients after the completion of immunotherapy. In the patient with massive lymphadenopathy and hepato- and splenomegaly, the size of the lymph nodes, spleen and liver decreased and neutrophil levels increased. Time of progression was 5–12 months, and in one patient partial remission has been maintained. The treatment was well-tolerated in most cases. Asymptomatic neutropenia and an infection with Candida glabrata were observed. Conclusions. Ofatumumab may be a new and safe therapeutic option for patients with CLL after a few lines of treatment.
Źródło:
Annals of Agricultural and Environmental Medicine; 2018, 25, 1; 56-59
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Aspekty immunologiczne terapii fotodynamicznej
Immunological features of photodynamic therapy
Autorzy:
Kawczyk-Krupka, A.
Czuba, Z.
Latos, W.
Mertas, A.
Król, W.
Simon-Sieroń, M.
Sieroń, A.
Powiązania:
https://bibliotekanauki.pl/articles/271622.pdf
Data publikacji:
2010
Wydawca:
Górnośląska Wyższa Szkoła Pedagogiczna im. Kardynała Augusta Hlonda
Tematy:
terapia fotodynamiczna
immunoterapia
immunoregulatory
phytpdunamic therapy
immunotherapy
immunoregulators
Opis:
Terapia fotodynamiczna (photodynamic therapy - PDT) jest metodą leczenia wybranych (przede wszystkim wczesnych) nowotworów i stanów przednowotworowych. Istotą tej metody jest selektywne niszczenie zmienionych chorobowo tkanek poprzez zadziałanie na nie światła laserowego o ściśle określonej długości fali. Zjawisko to umożliwia substancja - fotouczulacz, wychwytywana przez chorobowo zmienioną tkankę. Standardowo stosowanymi fouczulaczami są porfiryny, które są komponentą hemoglobiny. Działanie fotodynamiczne wywołuje trzy typy reakcji w naświetlanej tkance: bezpośredni efekt cytotoksyczny, pośredni efekt cytotoksyczny przez okluzję naczyń krwionośnych oraz wtórne działanie immunostymulujące i prozapalne. Spośród wymienionych sposobów działania, efekt immunostymulujący wydaje się być unikalny, zważywszy, że zarówno chemio- jak i radioterapia powodują upośledzenie funkcji układu immunologicznego. Wiele prac doświadczalnych wykazało, iż w trakcie terapii fotodynamicznej dochodzi do mobilizacji komórek immunokompetentnych: nacieku limfocytów, neutrofili, makrofagów, co wskazuje na aktywację procesu zapalnego. Mediatorami tego procesu są substancje wazoaktywne, składniki C3 dopełniacza, białka ostrej fazy, proteinazy, peroksydazy, reaktywne formy tlenu, cytokiny, czynniki wzrostu oraz inne substancje biorące udział w odpowiedzi immunologicznej. Podkreśla się, iż immunomodulacyjny efekt terapii fotodynamicznej związany jest także z wpływem na angiogenezę i aktywność metastatyczną komórek nowotworowych.
Photodynamic therapy (PDT) is a well-known method for the selective, non-invasive and effective treatment of precancerous and cancerous lesions due to the activation of photobiochemical processes that cause cytotoxicity. PDT is based on mutual reactions between laser irradiation and photosensitizers that accumulate in tissues and result in selective damage of pathological tissues. The anticancer effect of PDT is due to three main mechanisms. First, PDT is cytotoxic, with both necrotic and apoptotic effects. Second, PDT leads to the occlusion of blood and lymphatic vessels of the tumor. Third, PDT is associated with the modulation of immune and inflammatory responses. In addition to these mechanisms of cell death, there is a variety of events that occur during PDT that lead to and magnify the inactivation of tumor cells. Many studies have reported the infiltration of lymphocytes, neutrophils and macrophages into PDT-treated tissue, indicating activation of the immune response. The inflammatory process is mediated by factors such as vasoactive substances, components of the complement and clotting cascades, acute phase proteins, proteinases, peroxidases, reactive oxygen species, leukocyte chemoattractants, cytokines, growth factors and other immunoregulators. It is possible that immunomodulatory mechanisms of PDT could also influence angiogenesis and the invasiveness of tumor cells.
Źródło:
Journal of Ecology and Health; 2010, R. 14, nr 6, 6; 284-290
2082-2634
Pojawia się w:
Journal of Ecology and Health
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
In vitro co-stimulation of anti-tumor activity by soluble B7 molecules
Autorzy:
He, Wei
Hu, Zhong-Bo
Liu, Fang
Feng, Xian-Qi
Zou, Ping
Powiązania:
https://bibliotekanauki.pl/articles/1041178.pdf
Data publikacji:
2006
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
immunotherapy
tumor escape
gene fusion
recombinant fusion proteins
Opis:
In order to investigate the anti-tumor activity of a soluble B7-1/immunoglobulin G fusion protein and explore an effective method to eliminate immune escape of tumor cells, a recombinant vector encoding this fusion protein was constructed and constitutively expressed in Chinese hamster ovary cells. After purification with protein G affinity chromatography, the soluble fusion protein was tested for bioactivity. Results showed that the fusion protein could significantly increase the density of B7-1 molecules on WEHI-3 cells, a mouse leukemia cell line. Through allogeneic mixed lymphocyte tumor cultures, it was demonstrated that, with the presence of the first signal, it could also significantly enhance T cell activation and killing activity against WEHI-3 cells and interleukin-2 secretion by activated mouse T lymphocytes. The conclusion can be drawn that the soluble B7-IgG fusion protein has a potent capacity to generate or enhance anti-tumor immune response in vitro, and its clinical value deserves further investigation.
Źródło:
Acta Biochimica Polonica; 2006, 53, 4; 807-813
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Innovations in lung cancer treatment
Autorzy:
Sieńko, Anna
Rożenek, Karolina
Nalewaj, Piotr
Bożyk, Aleksandra
Krawczyk, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/1178237.pdf
Data publikacji:
2018
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
Immunotherapy
Lung cancer
Lung cancer treatment
targeted therapy
Opis:
Lung cancer is associated with one of the highest mortality rates among malignant tumors. It is the main death cause of men and women in Poland where over 15 000 men and 7 000 women die with this diagnosis annually. 1.7 million people die every year due to lung cancer in the world. Two main types of lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The history of lung cancer treatment begins with surgical approach followed by addition of chemotherapy and radiotherapy, which were used either separately or in combination depending on the stage of the lung cancer. Many somatic mutations were identified and molecularly targeted therapies could have been established. One of the oldest and the best known group of molecularly targeted drugs used in lung cancer treatment are tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR). First EGFR-TKI was gefitinib, which has been examined in clinical trials before erlotinib, afatinib, dacomitinib and osimertinib. EGFR-TKIs increased overall survival (OS) with significantly less side effects when compared to standard chemotherapy. Another group of molecularly targeted drugs are anaplastic lymphoma (ALK) kinase inhibitors such as crizotinib, alectinib and ceritinib. Another innovation which was introduced in NSCLC treatment was immunotherapy. Its effect is based on modification of immune system leading to activation of cytotoxic T lymphocytes (CTL). Currently nivolumab and pembrolizumab (anti-PD1 antibodies) as well as atezoliumab (anti-PD-L1 antibody) are being used in NSCLC patients. The discovery of innovative therapies for NSCLC patients resulted in significant extension of patients' life expectancy while minimizing the side effects of such therapy. Moreover, the quality of patients’ life was significantly improved. However, important problems still remain to be solved: overcoming the resistance in the course of molecularly targeted therapies and the lack of predictive factors that determine the effectiveness of immunotherapy.
Źródło:
World Scientific News; 2018, 93; 115-124
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Partial remission in patient with Richter syndrome: an „emergency” treatment with pixantrone
Autorzy:
Szwedyk, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/1035640.pdf
Data publikacji:
2020-06-30
Wydawca:
Medical Education
Tematy:
Richter syndrome
chemotherapy
chronic lymphocytic leukemia
immunotherapy
pixantrone
Opis:
Chronic lymphocytic leukemia is the most commonly recognized type of leukemia in adults. The appearance of systemic symptoms such as weight loss, fever, or local symptoms in the form of rapidly growing organomegaly, lymphadenopathy in a patient with CLL raises the suspicion of transformation into a high-grade lymphoma – defined as Richter syndrome which is usually associated with very poor prognosis. The described case concerns a 71-year-old patient with this diagnosis, in whom due to the confirmed resistance to subsequent lines of immuno- and chemotherapy, an „emergency” treatment with a modern chemotherapy drug from the aza-anthracendion group – pixantrone was used. Treatment with pixantrone was associated with a relatively good response, translating into partial remission (also in the area of infiltrative changes in the head and neck structures), stabilization of the course of the disease and, consequently, allowed to extend the patient’s life.
Źródło:
OncoReview; 2020, 10, 2; 52-56
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The current state of knowledge on small cell and non-small cell lung cancer and the position of durvalumab immunotherapy in lung cancer treatment
Autorzy:
Poboży, Kamil
Domańska, Julia
Domański, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/3200762.pdf
Data publikacji:
2023-01-24
Wydawca:
Medical Education
Tematy:
PD-L1
immunotherapy
durvalumab
neoplasm
oncology
SCLC
NSCLC
Opis:
Lung cancer is the second most frequently diagnosed cancer and the leading cause of cancer-related deaths in the world. These statistics make lung cancer one of the most important targets for modern medicine. The identification of multiple risk factors, including tobacco smoking, has been fundamental in understanding the disease. Late-stage detection is a significant contributor to the high mortality rate of lung cancer. Nonetheless, the role of screening is still debatable. The selection of therapy is primarily based on distinguishing between small-cell and non-small cell lung cancer. Despite the major differences in treatment, in both types in specific situations the treatment involves durvalumab – a monoclonal antibody targeting the programmed cell death ligand 1 molecule, which is often present on tumor cells and protects them against the patient’s immune system. The efficacy of durvalumab has been demonstrated in two randomized, multicenter clinical trials. The aim of this study is to summarize the current state of knowledge about lung cancer and durvalumab. Despite the current 5-year survival rate of 19% in lung cancer, the development of immunotherapeutics such as durvalumab may be the key to improving the unfavorable prognosis of lung cancer in the future.
Źródło:
OncoReview; 2022, 12, 4; 75-82
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Immunologiczne aspekty choroby Alzheimera
Immunological aspects of Alzheimer’s disease
Autorzy:
Wojtera, Marcin
Kłoszewska, Iwona
Sobów, Tomasz
Liberski, Paweł P.
Powiązania:
https://bibliotekanauki.pl/articles/1061410.pdf
Data publikacji:
2006
Wydawca:
Medical Communications
Tematy:
Alzheimer’s disease
immunotherapy
neuroinflammation
neurozapalenie
immunoterapia
choroba Alzhaimera
Opis:
Alzheimer’s disease (AD) is an incurable neurodegenerative disease, which is accompanied by chronic inflammation. The immune system has an important role in the process of the disease. The deposition of amyloid β (Aβ) protein is a key pathological feature in Alzheimer’s disease. This article reviews immunotherapeutic strategies against AD. In murine models of AD, both active and passive immunization against Aβ induces a marked reduction in an amyloid brain burden and an improvement in cognitive functions. The findings from murine studies lead to clinical studies. One Phase II clinical trial of active immunization against Aβ was discontinued after 18 patients developed meningoencephalitis. After this lesson learned, new immunotherapeutic strategies, including both active and passive immunization, are investigated in clinical centers.
Choroba Alzheimera (AD) jest nieuleczalną chorobą neurodegeneracyjną, której towarzyszy przewlekły proces zapalny. Układ immunologiczny może mieć istotny wpływ na przebieg procesu chorobowego. Głównym patologicznym wyznacznikiem choroby Alzheimera jest gromadzenie w obrębie mózgu złogów β-amyloidu. W obecnym artykule przedstawiono informacje na temat możliwości zastosowania immunoterapii w leczeniu choroby Alzheimera. Metody immunoterapeutyczne, mające usuwać amyloid β z chorych mózgów, dały bardzo pozytywne rezultaty w badaniach na zwierzętach. Zarówno metody aktywnej, jak i biernej immunizacji powodowały wyraźne zmniejszenie zawartości amyloidu w mózgach myszy transgenicznych oraz poprawę ich funkcji poznawczych. Bardzo dobre wyniki na modelach zwierzęcych pozwoliły przeprowadzić wstępne badania kliniczne. Ich wyniki są również obiecujące, choć obarczone ryzykiem zapalenia mózgu. Jedyne dotychczas badanie II Fazy z zastosowaniem szczepionki przeciwko Aβ zostało przerwane z powodu rozwoju u 18 pacjentów zapalenia opon mózgowych i mózgu. Obecnie ośrodkach badawczych pojawiają się nowe rodzaje technik immunoterapeutycznych.
Źródło:
Aktualności Neurologiczne; 2006, 6, 2; 108-115
1641-9227
2451-0696
Pojawia się w:
Aktualności Neurologiczne
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Mathematical Modeling of the Competition Between Acquired Immunity and Cancer
Autorzy:
Kolev, M.
Powiązania:
https://bibliotekanauki.pl/articles/908160.pdf
Data publikacji:
2003
Wydawca:
Uniwersytet Zielonogórski. Oficyna Wydawnicza
Tematy:
medycyna
matematyka
leukemia
acquired immunity
immunotherapy
antibodies
integro-differential equations
Opis:
In this paper we propose and analyse a model of the competition between cancer and the acquired immune system. The model is a system of integro-differential bilinear equations. The role of the humoral response is analyzed. The simulations are related to the immunotherapy of tumors with antibodies.
Źródło:
International Journal of Applied Mathematics and Computer Science; 2003, 13, 3; 289-296
1641-876X
2083-8492
Pojawia się w:
International Journal of Applied Mathematics and Computer Science
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Modelling Tumour-Immunity Interactions With Different Stimulation Functions
Autorzy:
Zhivkov, P.
Waniewski, J.
Powiązania:
https://bibliotekanauki.pl/articles/908163.pdf
Data publikacji:
2003
Wydawca:
Uniwersytet Zielonogórski. Oficyna Wydawnicza
Tematy:
medycyna
matematyka
ordinary differential equations
critical points
stability analysis
immunotherapy
Opis:
Tumour immunotherapy is aimed at the stimulation of the otherwise inactive immune system to remove, or at least to restrict, the growth of the original tumour and its metastases. The tumour-immune system interactions involve the stimulation of the immune response by tumour antigens, but also the tumour induced death of lymphocytes. A system of two non-linear ordinary differential equations was used to describe the dynamic process of interaction between the immune system and the tumour. Three different types of stimulation functions were considered: (a) Lotka-Volterra interactions, (b) switching functions dependent on the tumour size in the Michaelis-Menten form, and (c) Michaelis-Menten switching functions dependent on the ratio of the tumour size to the immune capacity. The linear analysis of equilibrium points yielded several different types of asymptotic behaviour of the system: unrestricted tumour growth, elimination of tumour or stabilization of the tumour size if the initial tumour size is relatively small, otherwise unrestricted tumour growth, global stabilization of the tumour size, and global elimination of the tumour. Models with switching functions dependent on the tumour size and the tumour to the immune capacity ratio exhibited qualitatively similar asymptotic behaviour.
Źródło:
International Journal of Applied Mathematics and Computer Science; 2003, 13, 3; 307-315
1641-876X
2083-8492
Pojawia się w:
International Journal of Applied Mathematics and Computer Science
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The effect of hymenoptera venom immunotherapy on neutrophils, interleukin 8 (IL-8) and interleukin 17 (IL-17)
Autorzy:
Pałgan, Krzysztof
Żbikowska-Gotz, Magdalena
Zacniewski, Robert
Bartuzi, Zbigniew
Powiązania:
https://bibliotekanauki.pl/articles/2116499.pdf
Data publikacji:
2020-10-20
Wydawca:
Instytut Medycyny Pracy im. prof. dra Jerzego Nofera w Łodzi
Tematy:
bee
IL-8
IL-17A
venom immunotherapy
wasp
neutrophils
Opis:
ObjectivesVenom immunotherapy (VIT) is an effective treatment method and is addressed to patients with a history of an anaphylactic reaction to Hymenoptera stings. However, the immunological mechanisms of protection have not been explained yet. The objective of this study was to analyze neutrophils, interleukin 8 (IL-8) and interleukin 17 (IL-17) before and after the initial phase of the immunotherapy.Material and MethodsOverall, 40 individuals, including 20 wasp venom sensitized and 20 bee venom sensitized patients, were included in the study. The patients had had a history of severe allergic reactions type III and IV according to Mueller’s classification. An ultra-rush VIT protocol was used in this study. The concentration of serum IL-8 and IL-17A was determined using the ELISA enzymatic method.ResultsThe authors demonstrated a significant rise in the IL-8 level after the immunotherapy, compared to baseline (14.9 vs. 24.7, p < 0.05). The rise in the neutrophils level was also noticeable but proved to be barely out of the range of statistical significance (4.3 vs. 5.0, p = 0.06). The shift in IL-17A was negligent and not statistically significant in the paired samples t-test (1.6 vs. 1.5, p = 0.34)ConclusionsVenom immunotherapy induces neutrophils and IL-8 activity after 2 days. After the desensitization, the level of IL-17A did not change.
Źródło:
International Journal of Occupational Medicine and Environmental Health; 2020, 33, 6; 811-817
1232-1087
1896-494X
Pojawia się w:
International Journal of Occupational Medicine and Environmental Health
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Clinical application of monoclonal antibodies in targeted therapy
Autorzy:
Superson, Maciej
(, Katarzyna Szmyt
Szymańska, Katarzyna
Walczak, Kamil
Wnorowski, Jeremi
Zarębski, Łukasz
Powiązania:
https://bibliotekanauki.pl/articles/454777.pdf
Data publikacji:
2019
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
cancer
inflammatory bowel diseases Alzheimer’s disease immunotherapy
targeted therapy
Opis:
Introduction. Recently, monoclonal antibodies (mAbs) have become powerful human therapeutics in the diagnosis and treatment of many diseases. Drugs based on mAbs are approved for the treatment of cardiovascular, respiratory, hematology, autoimmunology, and oncology diseases. Aim. To present the current state of knowledge about the application of mAbs in the therapy of various diseases such as cancer, autoimmune and Alzheimer’s diseases. Material and methods. We conducted a thorough review of the scientific literature from the following databases: EBSCO, PubMed, Science Direct, and Springer Link. Results. Currently, the Food and Drug Administration (FDA) has approved more than 50 therapeutic mAbs which are applied in various clinical trials. Action of mAb are based on various mechanisms, including directly targeting the cells, modifying the host response, recognizing and degrading molecules as well as delivering cytotoxic moieties. Conclusion. Despite some limitations including side effects, and therapeutic challenges, monoclonal antibodies are an attractive option for the development of new therapies and molecular drug targets against a wide range of common diseases due to their specificity and flexibility. MAbs are considered as a great hope for medicine, and effective and safe drugs in the treatment of various diseases.y
Źródło:
European Journal of Clinical and Experimental Medicine; 2019, 4; 338-346
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Salmonella and cancer: from pathogens to therapeutics
Autorzy:
Chorobik, Paulina
Czaplicki, Dominik
Ossysek, Karolina
Bereta, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1039520.pdf
Data publikacji:
2013
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
bacterial cancer therapy
immunotherapy
cancer vaccine
tumor targeting
Salmonella
VNP20009
Opis:
Bacterial cancer therapy is a concept more than 100 years old - yet, all things considered, it is still in early development. While the use of many passive therapeutics is hindered by the complexity of tumor biology, bacteria offer unique features that can overcome these limitations. Microbial metabolism, motility and sensitivity can lead to site-specific treatment, highly focused on the tumor and safe to other tissues. Activation of tumor-specific immunity is another important mechanism of such therapies. Several bacterial strains have been evaluated as cancer therapeutics so far, Salmonella Typhimurium being one of the most promising. S. Typhimurium and its derivatives have been used both as direct tumoricidal agents and as cancer vaccine vectors. VNP20009, an attenuated mutant of S. Typhimurium, shows significant native toxicity against murine tumors and was studied in a first-in-man phase I clinical trial for toxicity and anticancer activity. While proved to be safe in cancer patients, insufficient tumor colonization of VNP20009 was identified as a major limitation for further clinical development. Antibody-fragment-based targeting of cancer cells is one of the few approaches proposed to overcome this drawback.
Źródło:
Acta Biochimica Polonica; 2013, 60, 3; 285-297
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
CD40 stimulation induces differentiation of acute lymphoblastic leukemia cells into dendritic cells
Autorzy:
Łuczyński, Włodzimierz
Stasiak-Barmuta, Anna
Iłendo, Elżbieta
Krawczuk-Rybak, Maryna
Malinowska, Iwona
Mitura-Lesiuk, Małgorzata
Parfieńczyk, Adam
Szymański, Marcin
Powiązania:
https://bibliotekanauki.pl/articles/1041252.pdf
Data publikacji:
2006
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
immunotherapy
T-lymphocytes
CD40L
acute lymphoblastic leukemia
dendritic cells
Opis:
Despite the very high percentage of long-term remissions in acute lymphoblastic leukemia (ALL) in children, some of them suffer from recurrence of the disease. New treatment modalities, e.g. effective geno- and immunotherapy are needed. The use of neoplasmatic cells to present tumor antigens is one of the approaches in cancer vaccines. ALL cells lack the expression of costimulatory molecules and are poor antigen presenting cells (APCs) for T-cell activation. CD40/40L interaction stimulates B-cells to proliferate, differentiate, upregulate costimulatory molecules and increase antigen presentation. The aim of the study was to test the hypothesis that ALL cells can be turned into professional APCs by CD40L activation. Children with B-cell precursor ALL were enrolled into the study. Mononuclear cells from bone marrow or peripheral blood were stimulated with CD40L and interleukin 4. Results: 1) after culture we noted upregulation of all assessed costimulatory, adhesion and activatory molecules i.e. CD1a, CD11c, CD40, CD54, CD80, CD83, CD86, CD123, HLA class I and II; 2) CD40L activated ALL cells induced proliferation of allogeneic T-cells (measured by [3H]thymidine incorporation). These results confirm the possibility of enhancing the immunogenicity of ALL cells with the CD40L system and indicate that this approach can be used in immunotherapeutic trials.
Źródło:
Acta Biochimica Polonica; 2006, 53, 2; 377-382
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cardiovascular complications of selected antibodies used in oncological immunotherapy
Autorzy:
Kufel-Grabowska, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1062897.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
bevacizumab
immunotherapy
monoclonal antibodies
pertuzumab
trastuzumab
trastuzumab-emtansine
vascular endothelial growth factor
Opis:
Immunotherapy supports other therapeutic methods and is an important element in the fight against cancer. Its main tasks include stimulation and guidance of the immune system to fight cancer, inhibition of the mechanisms that block the immune system, and direct destruction of neoplastic cells. Different from chemotherapy or hormonal therapy, its mechanism of action is associated with a different profile of adverse events. HER2 receptor inhibitors may cause symptoms of heart failure, which usually recede, once the treatment has been discontinued. Bevacizumab, an anti-VEGF antibody, induces numerous cardiovascular complications, including arterial hypertension, arterial embolism, haemorrhage and haemoptysis as well as venous thromboembolism.
Źródło:
OncoReview; 2017, 7, 2; 78-82
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade
Autorzy:
Przybylski, Krzysztof
Majchrzak, Ewa
Weselik, Liucija
Golusiński, Wojciech
Powiązania:
https://bibliotekanauki.pl/articles/1398281.pdf
Data publikacji:
2018
Wydawca:
Index Copernicus International
Tematy:
head and neck squamouscell carcinoma
immunotherapy
CTLA - 4
PD - 1
nivolumab
pembrolizumab
Opis:
Treating patients with squamous cell carcinoma of the head and neck is a significant problem. There is an increase in the incidence of malignant neoplasms in this region. Surgery, radiotherapy and chemotherapy are often not sufficient methods of treatment. Thorough analysis of processes occurring in the tumor microenvironment has allowed to distinguish three stages that make up the reaction of the human body to hostile antigens, which are tumor antigens. Understanding these mechanisms has resulted in the introduction of a new term immune-oncology. It is an area of cancer treatment that focuses on use of the patient’s immune system to combat the disease. Immunotherapy has had positive effects in cancer patients. The use of immune checkpoint inhibitors, such as anti-CTLA-4 and PD-1 monoclonal antibodies has enabled the modulation of T cell functions, consequently eliminating immunosuppression in the tumor microenvironment. Clinical trials were conducted using nivolumab and ipilimumab, which confirmed their clinical usefulness. The approval by FDA of nivolumab in treatment of recurrent and metastatic squamous cell carcinoma of the head and neck has increased the overall survival time of patients as well as disease free survival. Statistical data indicate an advantage of immunotherapy over other treatment methods at an advanced stage of cancer. This work aims to discuss basic issues related to immunotherapy, in particular immunotherapy in patients with squamous cell carcinoma of the head and neck.
Źródło:
Polish Journal of Otolaryngology; 2018, 72, 6; 10-16
0030-6657
2300-8423
Pojawia się w:
Polish Journal of Otolaryngology
Dostawca treści:
Biblioteka Nauki
Artykuł

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies